Letters sent to healthcare professionals in May 2016

In May 2016, letters were sent regarding Nexplanon (etonogestrel implant) and ERWINASE.

From:
Medicines and Healthcare products Regulatory Agency
Published
15 June 2016
Therapeutic area:
Cancer and Obstetrics, gynaecology and fertility

In May 2016, letters were sent regarding:

  • Nexplanon (etonogestrel) implants have been found rarely in the vasculature and lung: an update regarding possible risks and complications regarding insertion, localisation and removal ()鈥攕ee also article in this issue

  • ERWINASE: notice of special handling instructions鈥攙ials of ERWINASE from batch 174g should be used with a 5-micron filter needle ()

Article citation: Drug Safety Update vol 9 issue 11, June 2016: 4.

Updates to this page

Published 15 June 2016